Ceryvyn Therapeutics (ASX:CYV) Forward PE Ratio: 0.00 (As of Jul. 11, 2026)


What is Ceryvyn Therapeutics Forward PE Ratio?

Ceryvyn Therapeutics ASX:CYV -7.69% Forward PE Ratio is 0.00 as of Jul. 11, 2026. The stock has 3 warning signs investors should review. Among 354 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 282485.59% on this metric.

Ceryvyn Therapeutics's Forward PE Ratio for today is 0.00.

Ceryvyn Therapeutics's PE Ratio without NRI for today is 0.57.

Ceryvyn Therapeutics's PE Ratio (TTM) for today is 0.00.

Ceryvyn Therapeutics  (ASX:CYV) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Ceryvyn Therapeutics Forward PE Ratio Related Terms

Ceryvyn Therapeutics Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Forward PE Ratio Chart

Ceryvyn Therapeutics Annual Data
Trend 2020-06
Forward PE Ratio
6.72

Ceryvyn Therapeutics Semi-Annual Data
2020-06
Forward PE Ratio 6.72

ASX:CYV vs VRTX, REGN, ALNY: Forward PE Ratio Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's Forward PE Ratio falls into.


Ceryvyn Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Ceryvyn Therapeutics (ASX:CYV) has a Forward PE Ratio of 0.00 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ceryvyn Therapeutics and its competitors. According to the industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 354 companies in the Biotechnology industry.
Is Ceryvyn Therapeutics' Forward PE Ratio too high?
Ceryvyn Therapeutics' current Forward PE Ratio is 0.00. Based on the distribution chart, Ceryvyn Therapeutics ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics' Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 354 companies for Forward PE Ratio. This places Ceryvyn Therapeutics in the lower half of its industry. The industry median Forward PE Ratio is 21.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.90, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ceryvyn Therapeutics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Forward PE Ratio is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.